DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy

Phase 2

Active, not recruiting

Conditions: Adenocarcinoma of Prostate

Interventions: Drug: Degarelix
Radiation: Pelvic Radiotherapy

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-16

Lead Sponsor: UNICANCER

Target Recruit Count: 120

Registration Number: NCT01994239

Locations: 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷
Clinique Sainte-Marguerite, Hyeres, France
🇫🇷
Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France

and more 36 locations

Chronic Toxicities Related to Treatment in Patients With Localized Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer Nos Metastatic Recurrent
Early Lung Cancer

Interventions: Procedure: blood sampling

First Posted Date: 2013-11-25

Last Posted Date: 2024-10-18

Lead Sponsor: UNICANCER

Target Recruit Count: 14750

Registration Number: NCT01993498

Locations: 🇫🇷
Gustave roussy, Villejuif, France

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Metastatic Prostate Cancer

Interventions: Radiation: radiotherapy
Drug: abiraterone acetate
Other: Androgen Deprivation Therapy
Drug: Docetaxel

First Posted Date: 2013-10-08

Last Posted Date: 2024-11-11

Lead Sponsor: UNICANCER

Target Recruit Count: 1173

Registration Number: NCT01957436

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇪🇸
ICO Girona - Hospital Josep Trueta, Girona, Spain

and more 74 locations

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Phase 3

Active, not recruiting

Conditions: Adenocarcinoma of Prostate
Progression of Prostate Cancer

Interventions: Radiation: Pelvic radiotherapy
Drug: Cabazitaxel
Radiation: prostate radiotherapy

First Posted Date: 2013-09-27

Last Posted Date: 2024-04-09

Lead Sponsor: UNICANCER

Target Recruit Count: 761

Registration Number: NCT01952223

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab + Afatinib
Drug: Cetuximab

First Posted Date: 2013-08-09

Last Posted Date: 2018-05-08

Lead Sponsor: UNICANCER

Target Recruit Count: 75

Registration Number: NCT01919879

Locations: 🇫🇷
Institute de Cancérologie de la Loire, Nantes, France

Abiraterone Acetate in Molecular Apocrine Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Abiraterone Acetate

First Posted Date: 2013-04-29

Last Posted Date: 2021-02-23

Lead Sponsor: UNICANCER

Target Recruit Count: 34

Registration Number: NCT01842321

Locations: 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷
Chu de Brest - Hôpital Morvan, Brest, France
🇫🇷
Ico - Site Paul Papin, Angers, France

and more 33 locations

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Phase 3

Active, not recruiting

Conditions: Primary Non-metastatic Breast Cancer
Who Remain Disease-free

Interventions: Drug: Placebo
Drug: Everolimus

First Posted Date: 2013-03-06

Last Posted Date: 2025-05-14

Lead Sponsor: UNICANCER

Target Recruit Count: 1278

Registration Number: NCT01805271

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Gustave Roussy, Villejuif, France

Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

Phase 3

Active, not recruiting

Conditions: Cancer of the Rectum

Interventions: Radiation: Radiotherapy 50 Gy
Drug: mFolfirinox
Drug: Capecitabine
Procedure: TME surgery
Drug: mFolfox6 or capecitabine

First Posted Date: 2013-03-05

Last Posted Date: 2024-09-30

Lead Sponsor: UNICANCER

Target Recruit Count: 461

Registration Number: NCT01804790

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷
ICO - Site Paul Papin, Angers, France
🇫🇷
Centre hospitalier Universitaire d'Amiens, Amiens, France

and more 32 locations

Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery

Phase 1

Completed

Conditions: Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy

Interventions: Drug: Abiraterone

First Posted Date: 2013-01-30

Last Posted Date: 2022-05-19

Lead Sponsor: UNICANCER

Target Recruit Count: 47

Registration Number: NCT01780220

Locations: 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
Institut de Cancérologie de l'ouest/René Gauducheau, Saint-Herblain, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 2 locations

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer

Completed

Conditions: Metastatic
Breast Cancer

Interventions: Drug: Bevacizumab
Drug: paclitaxel

First Posted Date: 2012-12-10

Last Posted Date: 2023-01-27

Lead Sponsor: UNICANCER

Target Recruit Count: 510

Registration Number: NCT01745757

Locations: 🇫🇷
Hôpital Européen, Marseille, France
🇫🇷
Centre Hospitalier, Roanne, France
🇫🇷
Centre Paul Strauss, Strasbourg, France

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy